繼華為小米(01810.HK)後 傳OPPO、vivo將推自研ISP芯片
據騰訊《深網》報道,一線手機生產商OPPO和vivo即將發布自研ISP芯片。
據悉,OPPO自研芯片項目團隊已有上千人,首款產品是和小米(01810.HK)澎湃C1類似的ISP芯片,將在明年年初上市的Find X4系列手機上首次發布。
而vivo亦早在兩年前就自建了芯片團隊,名為「悅影」,目前已有500至600人,首款產品同樣是影像方向,將在今年下半年上市的X70系列手機上首次發布。
報道又引述消息指,vivo同時推動自研SOC計劃,未來可能會替代部分高通和聯發科芯片。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.